The company’s leading compound, called CLR 131, is in clinical trials for blood cancers such as multiple myeloma. But the UW-Madison researchers will now test whether that compound, combined with beam radiation, can treat head and neck cancers.
The research is part of the National Cancer Institute’s Specialized Program of Research Excellence program.
“While we remain focused on advancing CLR 131 as a therapy for hematologic malignancies, we look forward to seeing the outcomes of the University’s research,” Cellectar President and CEO Jim Caruso said. “We are grateful for our long-standing relationship with the University of Wisconsin and congratulate them, and in particular, Dr. Paul Harari, chair of human oncology, who oversaw the SPORE grant application.”
See the release:
http://investor.cellectar.com/releasedetail.cfm?ReleaseID=988697
;
